Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction

Award Number: R01DA064139
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction - Abstract The advent of combination anti-retroviral therapy (cART) has prolonged the lifespans of people living with HIV. However, upon cessation of ART treatment the virus quickly rebounds. One of the likely causes for this rebound is the rapid seeding and establishment of viral reservoirs in multiple tissue compartments including the central nervous system (CNS). The CNS is a sanctuary site for HIV due to the presence of barriers such as the blood brain barrier (BBB) and choroid plexus. These structures significantly limit the CNS delivery of ART drugs which prevents control of viral replication and the associated negative effects on cognition. Therefore, novel strategies need to be developed for both treatment and viral reservoir clearance in the brain. We recently optimized a novel technique called focused ultrasound induced blood brain barrier opening (FUSS-BBBO) to overcome BBB permeability constraints. FUS-BBBO has been safely and successfully used to deliver anticancer chemotherapy drugs directly into brain tumors in human patients and target large brain regions in rodents and nonhuman primates for gene delivery. FUS-BBBO uses low-intensity ultrasound with systemically administered microbubbles, which oscillate in blood vessels at the ultrasound focus, resulting in safe, localized, temporary (6- 24 h), and reversible opening of the BBB. FUS-BBBO has been successfully used to deliver proteins, small molecules, and viral vectors without inflicting detectable tissue damage in both rodents and nonhuman primates. Therefore, in the present study, we will use FUS-BBBO to deliver long-acting cART (Cabotegravir and Islatravir) drugs in conjunction with an anti-inflammatory delta-9-tetrahydrocannabinol treatment to two specific areas of the brain (basal ganglia and hippocampus) known to be targeted by HIV/SIV for better control of viral replication and persistence. In addition, we will use Adeno-Associated vector particles to deliver a gene therapeutic blocking SIV infection (anti-SIV glycosylphosphatidylinositol-anchored single chain variable fragments (scFvs) to brain resident macrophages and microglia for durable suppression of viral replication in the brain following cART interruption. These new technologies will be tested in the SIV-infected rhesus macaque model that shows consistent CNS infection, and neuroinflammation under suppressive cART. While both Cabotegravir and Islatravir have been independently demonstrated to reduce plasma viremia in the human and rhesus macaques, our studies will for the first time directly test the efficacy of these drugs administered using subdermal nanofluidic implants on HIV/SIV replication in brain resident perivascular macrophages and microglia. The proposed studies will help establish the FUS-BBBO method to increase cART drug delivery to the brain for reduction of neuro- HIV/SIV infection and its adverse effects on brain function. Finally, these studies will also help evaluate the safety and efficacy of FUS-BBBO delivery of long-acting cARTs and novel AAV-delivered anti-HIV/SIV inhibitors to the brain.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,825,990 )
2025	2025	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Drug Use and Addiction Research Programs	001	1	9/3/2025	NEW	$0
2025	2025	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Drug Use and Addiction Research Programs	000	1	8/13/2025	NEW	$1,825,990
														Subtotal = $1,825,990

Grand Total All Awards = $1,825,990

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction

Award Number: R01DA064139

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer